

MSCI Indexes

Innovation Creates Opportunity

Within Life Sciences


The pharmaceutical industry is experiencing a faster pace of disruption thanks to frequent technological breakthroughs.

This results in more innovative treatments being developed, and in less time than ever before.



2021 was a record year for clinical drug trials using biotech modalities:


1 A clinical drug trial is a study performed on people to evaluate a medical intervention (a treatment or procedure)



Behind every new treatment is an innovative company working to develop it. Thus, as the number of clinical trials grows, so too does the opportunity for investment.


The FDA Approval Process

Companies in the life sciences industry go through many stages as they attempt to bring their product to market. Their likelihood of FDA approval increases with each successive trial phase.



Current Trends in Biotech


Analysts expect next-gen biotech modalities to generate \$680 billion in annual revenues by 2028.



Global adoption of these innovative treatments could drastically shrink the sales gap between conventional medicines and biotech.

Distribution of Sales Moves Closer Together

Sales by technology area




What's the difference between conventional medicine and biotechnology?

Conventional	Biotechnology	
Chemical structure	Simple	Complex
Development process	Empirical screening	Biological engineering
Basis of research	Plants, microbes, organisms	RNA, DNA, hormones
Method of delivery	Typically a pill	Typically a shot or infusion

A Unique Challenge

Drug development is complex, costly, and risky

While a disease may have thousands of potential medicines, only one will ultimately receive FDA approval. This poses a risk for early-stage companies and their investors.



Introducing the MSCI Life Sciences Indexes

Developed in collaboration with Royalty Pharma, these unique solutions are the latest addition to MSCI's suite of thematic indexes.

Each index focuses on an aspect of life sciences such as oncology, virology, and other key biotech growth categories.



ACWI IMI Virology
Virology is the study, prevention, diagnosis, and treatment of viral infections.



ACWI IMI Immuno-Oncology
Oncology is the branch of medicine that deals with the prevention, diagnosis, and treatment of cancer.



Biotech Advance
Companies associated with research, development, and commercialization of products for treating a broad range of diseases and disorders.

MSCI  Learn more about the MSCI Life Sciences Indexes.

Powering better investment decisions. [msci.com](https://www.msci.com)

© 2023 MSCI Inc. All rights reserved

ABOUT MSCI
MSCI is a leading provider of critical decision support tools and services for the global investment community. With over 50 years of expertise in research, data and technology, we power better investment decisions by enabling clients to understand and analyze key drivers of risk and return and confidently build more effective portfolios. We create industry-leading research-enhanced solutions that clients use to gain insight into and improve transparency across the investment process. To learn more, please visit [msci.com](https://www.msci.com)

MSCI notice and disclaimer
The information contained herein (the "Information") may not be reproduced or disseminated in whole or in part without prior written permission from MSCI. The Information may not be used to verify or correct other data, to create any derivative works, to create indexes, risk models, or analytics, or in connection with issuing, offering, sponsoring, managing or marketing any securities, portfolios, financial products or other investment vehicles. Historical data and analysis should not be taken as an indication or guarantee of any future performance, analysis, forecast or prediction. None of the Information or MSCI index or other product or service constitutes an offer to buy or sell, or a promotion or recommendation of, any security, financial instrument or product or trading strategy. Further, none of the Information or any MSCI index is intended to constitute investment advice or a recommendation to make (or refrain from making) any kind of investment decision and may not be relied on as such. The Information is provided "as is" and the user of the Information assumes the entire risk of any use it may make or permit to be made of the Information. NONE OF MSCI INC. OR ANY OF ITS SUBSIDIARIES OR ITS OR THEIR DIRECT OR INDIRECT SUPPLIERS OR ANY THIRD PARTY INVOLVED IN MAKING OR COMPILING THE INFORMATION (EACH AN "INFORMATION PROVIDER") MAKES ANY WARRANTIES OR REPRESENTATIONS AND, TO THE MAXIMUM EXTENT PERMITTED BY LAW, EACH INFORMATION PROVIDER HEREBY EXPRESSLY DISCLAIMS ALL IMPLIED WARRANTIES, INCLUDING WARRANTIES OF MERCHANTABILITY AND FITNESS FOR A PARTICULAR PURPOSE, WITHOUT LIMITING ANY OF THE FOREGOING AND TO THE MAXIMUM EXTENT PERMITTED BY LAW IN NO EVENT SHALL ANY OF THE INFORMATION PROVIDERS HAVE ANY LIABILITY REGARDING ANY OF THE INFORMATION FOR ANY DIRECT, INDIRECT, SPECIAL, PUNITIVE, CONSEQUENTIAL (INCLUDING LOST PROFITS) OR ANY OTHER DAMAGES EVEN IF NOTIFIED OF THE POSSIBILITY OF SUCH DAMAGES. The foregoing shall not exclude or limit any liability that may not be applicable by law be excluded or limited. Privacy notice: For information about how MSCI collects and uses personal data, please refer to our Privacy Notice at <https://www.msci.com/privacy-pledge>.